Aurobindo Pharma Ltd - Fall Short of Expectations Amidst Mixed Market Performance
Gross margins decreased by 23 basis points QoQ, and EBITDA margins fell by 67 basis points QoQ, reflecting the pressure on profitability from...
245 Views
Axis Top Picks for the month of July 2024
The Axis Top Picks Basket delivered an excellent return of 11.8% in the last three months against the 7.5% return posted by Nifty 50 over the same...
411 Views
Axis Top Picks for the Month of June 2024
The Axis Top Picks Basket delivered an excellent return of 5.4% in the last three months against the 2.5% return posted by Nifty 50, thereby...
422 Views
Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern. Maintain ADD
EBITDA (+68% YoY) was led by 17% sales growth (-4% QoQ US but up 18% YoY, +10% EU, and +49% YoY in growth markets), higher gross margin (+490 bps YoY)
339 Views
Aurobindo Pharma (4QFY24): Strong Q4, Eugia’s USFDA Issues Key Concern.
ARBP expects to maintain US oral solid business growth momentum, led by new launches and volume gain in the base business
293 Views